Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret Littlejohn

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Plos One|November 10, 2011
Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTJennifer Audsley, Eric C Seaberg, Joe Sasadeusz, et al.
Journal of Medical Virology|June 20, 2012
In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infectionLiza M Cabuang, Tim Shaw, Margaret Littlejohn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Hepatology (Baltimore, Md.)|June 1, 2010
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markersAlexander J V Thompson, Tin Nguyen, David Iser, et al.
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Cell Death & Disease|June 24, 2021
Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical modelsMichelle P Clark, Thao Huynh, Shringar Rao, et al.
Virology|July 27, 2010
HBV mutations in untreated HIV-HBV co-infection using genomic length sequencingJennifer Audsley, Margaret Littlejohn, Lilly Yuen, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Journal of Hepatology|May 30, 2024
CRISPR-Cas13b-mediated suppression of HBV replication and protein expressionLaura C McCoullough, Mohamed Fareh, Wenxin Hu, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Plos One|November 10, 2011
Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTJennifer Audsley, Eric C Seaberg, Joe Sasadeusz, et al.
Journal of Medical Virology|June 20, 2012
In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infectionLiza M Cabuang, Tim Shaw, Margaret Littlejohn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Hepatology (Baltimore, Md.)|June 1, 2010
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markersAlexander J V Thompson, Tin Nguyen, David Iser, et al.
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Cell Death & Disease|June 24, 2021
Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical modelsMichelle P Clark, Thao Huynh, Shringar Rao, et al.
Virology|July 27, 2010
HBV mutations in untreated HIV-HBV co-infection using genomic length sequencingJennifer Audsley, Margaret Littlejohn, Lilly Yuen, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Journal of Hepatology|May 30, 2024
CRISPR-Cas13b-mediated suppression of HBV replication and protein expressionLaura C McCoullough, Mohamed Fareh, Wenxin Hu, et al.
Pageof 6